Clean Screen® XCEL Solid Phase Extraction Columns

The United States has seen an increased usage and abuse of fentanyl and fentanyl analogs over the last decade, increasing the list of derivatives that forensic toxicologists need the ability to identify. Meanwhile, typically employed immunoassays have proven to be inaccurate for the initial detection of these novel, synthetic drugs.

In this application note, a universal extraction approach for both current compounds and emerging analytes is illustrated, involving a three-step solid phase extraction procedure for the identification of fentanyl and its major urinary metabolite norfentanyl along with eleven additional synthetic opioid compounds.

Benzodiazepines are prescribed for the treatment of anxiety, insomnia, muscle spasms, alcohol withdrawal and seizure prevention. They are also recurrently utilized as illegal recreational drugs and, similar to other commonly abused compounds, “ legal” alternatives have been developed in an attempt to bypass the controlled substances act. This application note describes a method for the simultaneous detection of prescription and synthetic Benzodiazepine in urine using UCT’s Clean Screen® XCEL I extraction columns in conjunction with the Selectra®DA HPLC column.

With the use of LC/MS/MS and full screen (QTrap methodology) the complete detection of both illicit and prescribed drugs can be accomplished easily with a simple solid phase extraction preparation. This application note shows the development of a rapid, highly sensitive qualitative method for the analysis of acidic, neutral, and basic compounds in biological fluids using Clean Screen XCEL® I solid phase extraction columns. The sample preparation is minimized while efficiently extracting a large group of representative compounds.

Cannabis is the most widely used illegal substance in the world, where humans smoke or ingest it for its psychotropic effects. Analytical methods for quantifying cannabinoids and their metabolites exist for plasma, blood, urine, hair, sweat and oral fluid. This study explores the efficiency of polymeric versus silica based solid phase columns for the extraction of Delta-9-THC and its primary metabolite 11-nor-9-Carboxy-THC from oral fluid prepared using the Quantisal™ Synthetic Negative Oral Fluid diluted with extraction buffer.

This application note describes a method that is used for the extraction of THC, THC-OH, and THC-COOH in whole blood. LC/MS/MS instrumentation is used for analysis with a linear range of 1 ng/mL to 100 ng/mL with average recoveries of individual cannabinoids found to be greater than 95%.

This application note describes a method that can be used for the extraction of Psilocin and Psilocybin in urine. LC/MS/MS instrumentation is used for analysis with a linear range of 10 ng/mL to 1000 ng/mL with average recoveries of individual cannabinoids found to be greater than 85%.

This application note presents a method for the extraction of AM2201 and metabolites in urine. LC/MS/MS instrumentation is used for analysis with a linear range of 1 ng/mL to 100 ng/mL with average recoveries found to be greater than 90%.

The FASt® column is a novel approach to improved sample preparation for LC/MS analysis. The column employs a one step process to prepare urine samples for analysis of multiple drugs and metabolites. By quickly and efficiently reducing the amount of unwanted matrix (through sorbent adsorption) and particulates (filtering through special frits) in the final sample, the analysis can proceed with less chance of matrix suppression and LC column clogging. Watch this video to find out more.

From rhinos to chemical warfare agents, we bring you the latest in forensics and toxicology